Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ CompletedNot Applicable A Multi-Center, Open Label Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease
The purpose of this study is to determine the efficacy of chitosan chewing gum (K2CG) in reducing serum phosphorus in subjects with chronic kidney disease.
/ CompletedNot Applicable A Single Blind Pharmacodynamic Study to Assess the Phosphate Binding Characteristics of K2CG Chewing Gum
The specific purpose of this study is to describe the characteristics of the K2CG chewing gum, specifically as it relates to duration of gum chewing (exposure), timing of gum chewing in relation to a meal, and dose of K2CG chewing gum.
/ CompletedNot Applicable Assessment of the Relationship Between Salivary Phosphorus and Level of Kidney Function
The specific purpose of this study is to describe the relationship between salivary phosphorus and kidney function, specifically as it relates to serum phosphorus, FGF23, PTH, vitamin D status and urinary excretion of phosphorus.
100 Clinical Results associated with CM&D Pharma Ltd.
0 Patents (Medical) associated with CM&D Pharma Ltd.
100 Deals associated with CM&D Pharma Ltd.
100 Translational Medicine associated with CM&D Pharma Ltd.